Literature DB >> 12013535

Breast cancer and the immune system: opportunities and pitfalls.

T A Plunkett1, I Correa, D W Miles, J Taylor-Papadimitriou.   

Abstract

The identification of tumor-associated antigens, and advances in our understanding of human immunology, have resulted in renewed interest in tumor immunology. A variety of approaches have been utilized in recent years against different tumor types. The results from some of these studies have been encouraging, but it is not yet clear whether they will be applicable to patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12013535     DOI: 10.1023/a:1014743232598

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.698


  45 in total

Review 1.  Ganglioside vaccines with emphasis on GM2.

Authors:  P Livingston
Journal:  Semin Oncol       Date:  1998-12       Impact factor: 4.929

2.  Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability.

Authors:  N Romani; D Reider; M Heuer; S Ebner; E Kämpgen; B Eibl; D Niederwieser; G Schuler
Journal:  J Immunol Methods       Date:  1996-09-27       Impact factor: 2.303

3.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors:  J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

4.  MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral.

Authors:  V Apostolopoulos; C Osinski; I F McKenzie
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

5.  Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide.

Authors:  M Reddish; G D MacLean; R R Koganty; J Kan-Mitchell; V Jones; M S Mitchell; B M Longenecker
Journal:  Int J Cancer       Date:  1998-06-10       Impact factor: 7.396

6.  Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.

Authors:  G D MacLean; M A Reddish; R R Koganty; B M Longenecker
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-01

7.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

Authors:  M L Disis; E Calenoff; G McLaughlin; A E Murphy; W Chen; B Groner; M Jeschke; N Lydon; E McGlynn; R B Livingston
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

Review 8.  Human tumor-infiltrating lymphocytes: a marker of host response.

Authors:  B M Vose; M Moore
Journal:  Semin Hematol       Date:  1985-01       Impact factor: 3.851

9.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

Authors:  A Y Huang; P Golumbek; M Ahmadzadeh; E Jaffee; D Pardoll; H Levitsky
Journal:  Science       Date:  1994-05-13       Impact factor: 47.728

10.  High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours.

Authors:  E Venetsanakos; I Beckman; J Bradley; J M Skinner
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  4 in total

Review 1.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

2.  ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma.

Authors:  Ivan Jovanovic; Gordana Radosavljevic; Maja Mitrovic; Vanda Lisnic Juranic; Andrew N J McKenzie; Nebojsa Arsenijevic; Stipan Jonjic; Miodrag L Lukic
Journal:  Eur J Immunol       Date:  2011-07       Impact factor: 5.532

3.  Quantification of the CD8+ T cell response against a mucin epitope in patients with breast cancer.

Authors:  Konrad Kokowski; Ulf Harnack; David C Dorn; Gabriele Pecher
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-03-31       Impact factor: 4.291

4.  T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

Authors:  Achim Rody; Uwe Holtrich; Laos Pusztai; Cornelia Liedtke; Regine Gaetje; Eugen Ruckhaeberle; Christine Solbach; Lars Hanker; Andre Ahr; Dirk Metzler; Knut Engels; Thomas Karn; Manfred Kaufmann
Journal:  Breast Cancer Res       Date:  2009-03-09       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.